MA35458B1 - Variants du facteur de croissance des fibroblastes 21 - Google Patents
Variants du facteur de croissance des fibroblastes 21Info
- Publication number
- MA35458B1 MA35458B1 MA36861A MA36861A MA35458B1 MA 35458 B1 MA35458 B1 MA 35458B1 MA 36861 A MA36861 A MA 36861A MA 36861 A MA36861 A MA 36861A MA 35458 B1 MA35458 B1 MA 35458B1
- Authority
- MA
- Morocco
- Prior art keywords
- variants
- growth factor
- fibroblast growth
- fgf21
- dyslipidemia
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 3
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542906P | 2011-10-04 | 2011-10-04 | |
| PCT/US2012/057053 WO2013052311A1 (en) | 2011-10-04 | 2012-09-25 | Fibroblast growth factor 21 variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35458B1 true MA35458B1 (fr) | 2014-09-01 |
Family
ID=46964112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36861A MA35458B1 (fr) | 2011-10-04 | 2014-03-27 | Variants du facteur de croissance des fibroblastes 21 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8541369B2 (esLanguage) |
| EP (1) | EP2763689B1 (esLanguage) |
| JP (1) | JP6060167B2 (esLanguage) |
| KR (1) | KR20140059271A (esLanguage) |
| CN (1) | CN103906530B (esLanguage) |
| AP (1) | AP2014007532A0 (esLanguage) |
| AR (1) | AR087973A1 (esLanguage) |
| AU (1) | AU2012318956A1 (esLanguage) |
| BR (1) | BR112014007532A2 (esLanguage) |
| CA (1) | CA2843520A1 (esLanguage) |
| CL (1) | CL2014000801A1 (esLanguage) |
| CO (1) | CO6910165A2 (esLanguage) |
| CR (1) | CR20140142A (esLanguage) |
| DO (1) | DOP2014000050A (esLanguage) |
| EA (1) | EA201490521A1 (esLanguage) |
| EC (1) | ECSP14013285A (esLanguage) |
| ES (1) | ES2548214T3 (esLanguage) |
| IL (1) | IL230754A0 (esLanguage) |
| IN (1) | IN2014CN00782A (esLanguage) |
| MA (1) | MA35458B1 (esLanguage) |
| MX (1) | MX2014004159A (esLanguage) |
| PE (1) | PE20142044A1 (esLanguage) |
| PH (1) | PH12014500740A1 (esLanguage) |
| SG (1) | SG11201401792UA (esLanguage) |
| TN (1) | TN2014000096A1 (esLanguage) |
| TW (1) | TWI461435B (esLanguage) |
| WO (1) | WO2013052311A1 (esLanguage) |
| ZA (1) | ZA201400882B (esLanguage) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
| PE20141727A1 (es) | 2011-07-01 | 2014-11-26 | Ngm Biopharmaceuticals Inc | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas |
| BR112014028413A2 (pt) * | 2012-05-15 | 2017-11-07 | Lilly Co Eli | usos terapêuticos de proteínas do fator de crescimento de fibroblastos 21 . |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| CN104364261B (zh) * | 2012-06-11 | 2017-04-05 | 伊莱利利公司 | 成纤维细胞生长因子21变体 |
| CA2892152A1 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9925242B2 (en) | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
| MX377380B (es) | 2013-10-28 | 2025-03-10 | Ngm Biopharmaceuticals Inc | Modelos de cáncer y métodos asociados. |
| AU2015209131B2 (en) | 2014-01-24 | 2020-06-25 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| UA123763C2 (uk) | 2014-10-23 | 2021-06-02 | Енджіем Байофармасьютикалз, Інк. | Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19 |
| SMT202100388T1 (it) | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| WO2017220706A1 (en) * | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
| WO2018039557A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN106432509B (zh) * | 2016-09-13 | 2019-05-21 | 河南师范大学 | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 |
| CN106220724B (zh) * | 2016-09-13 | 2019-10-11 | 河南师范大学 | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 |
| CN106397607A (zh) * | 2016-09-13 | 2017-02-15 | 河南师范大学 | 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用 |
| JP7181886B2 (ja) | 2017-03-14 | 2022-12-01 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 免疫グロブリンのＦｃ部分を含む二重標的融合タンパク質 |
| AU2018329850A1 (en) | 2017-09-08 | 2020-04-23 | Bristol-Myers Squibb Company | Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH) |
| US20200376080A1 (en) | 2017-12-22 | 2020-12-03 | Novartis Ag | Methods of treating metabolic disorders with fgf21 variants |
| EP3749683A4 (en) * | 2018-02-08 | 2022-03-16 | Sunshine Lake Pharma Co., Ltd. | FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF |
| CN112601517A (zh) | 2018-07-03 | 2021-04-02 | 百时美施贵宝公司 | Fgf-21配制品 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| KR20210137093A (ko) * | 2019-03-05 | 2021-11-17 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 폴리펩티드 분자 및 이의 적용 |
| CN111944055B (zh) | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| IL294534A (en) | 2020-01-08 | 2022-09-01 | Bristol Myers Squibb Co | Fgf-21 conjugate formulations |
| CN115322794B (zh) | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| EP4192495A1 (en) | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| KR102495299B1 (ko) * | 2020-11-03 | 2023-02-06 | 토드제약 주식회사 | Fgf21의 열탄력성을 이용한 fgf21 생산 방법 |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| JP2024527613A (ja) | 2021-07-14 | 2024-07-25 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | 代謝性障害のための融合ポリペプチド |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| JP4477013B2 (ja) * | 2003-12-10 | 2010-06-09 | イーライ リリー アンド カンパニー | 線維芽細胞成長因子２１の突然変異タンパク質 |
| MX2007002616A (es) * | 2004-09-02 | 2007-05-16 | Lilly Co Eli | Muteinas de factor de crecimiento de fibroblasto 21. |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| CN104163864B (zh) | 2007-03-30 | 2017-08-01 | Ambrx公司 | 经修饰fgf‑21多肽和其用途 |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
| EP4353247A3 (en) | 2009-05-05 | 2024-07-17 | Amgen Inc. | Fgf21 mutants and uses thereof |
-
2012
- 2012-09-20 AR ARP120103466A patent/AR087973A1/es unknown
- 2012-09-21 TW TW101134800A patent/TWI461435B/zh not_active IP Right Cessation
- 2012-09-25 SG SG11201401792UA patent/SG11201401792UA/en unknown
- 2012-09-25 ES ES12766847.3T patent/ES2548214T3/es active Active
- 2012-09-25 BR BR112014007532A patent/BR112014007532A2/pt not_active IP Right Cessation
- 2012-09-25 MX MX2014004159A patent/MX2014004159A/es unknown
- 2012-09-25 AU AU2012318956A patent/AU2012318956A1/en not_active Abandoned
- 2012-09-25 KR KR1020147008644A patent/KR20140059271A/ko not_active Withdrawn
- 2012-09-25 PE PE2014000472A patent/PE20142044A1/es not_active Application Discontinuation
- 2012-09-25 EA EA201490521A patent/EA201490521A1/ru unknown
- 2012-09-25 CN CN201280048530.2A patent/CN103906530B/zh not_active Expired - Fee Related
- 2012-09-25 IN IN782CHN2014 patent/IN2014CN00782A/en unknown
- 2012-09-25 US US13/626,308 patent/US8541369B2/en active Active
- 2012-09-25 JP JP2014534596A patent/JP6060167B2/ja active Active
- 2012-09-25 AP AP2014007532A patent/AP2014007532A0/xx unknown
- 2012-09-25 EP EP12766847.3A patent/EP2763689B1/en active Active
- 2012-09-25 PH PH1/2014/500740A patent/PH12014500740A1/en unknown
- 2012-09-25 WO PCT/US2012/057053 patent/WO2013052311A1/en not_active Ceased
- 2012-09-25 CA CA2843520A patent/CA2843520A1/en not_active Abandoned
-
2013
- 2013-08-13 US US13/965,243 patent/US8883726B2/en active Active
-
2014
- 2014-01-30 IL IL230754A patent/IL230754A0/en unknown
- 2014-02-05 ZA ZA2014/00882A patent/ZA201400882B/en unknown
- 2014-03-06 DO DO2014000050A patent/DOP2014000050A/es unknown
- 2014-03-06 TN TNP2014000096A patent/TN2014000096A1/en unknown
- 2014-03-17 CO CO14057034A patent/CO6910165A2/es unknown
- 2014-03-27 CR CR20140142A patent/CR20140142A/es unknown
- 2014-03-27 MA MA36861A patent/MA35458B1/fr unknown
- 2014-04-02 CL CL2014000801A patent/CL2014000801A1/es unknown
- 2014-04-04 EC ECSP14013285 patent/ECSP14013285A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35458B1 (fr) | Variants du facteur de croissance des fibroblastes 21 | |
| EA201492053A1 (ru) | Белки фактора роста фибробластов 21 | |
| EA201492064A1 (ru) | Варианты фактора роста фибробластов 21 | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CY1119596T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
| EA201390060A1 (ru) | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
| EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| UA104626C2 (ru) | Анти-vegf антитело и его применение | |
| EA201270480A1 (ru) | Новые соединения | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| EA201200551A1 (ru) | Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения | |
| AR080685A1 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| CR20130264A (es) | Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2 | |
| EA201100032A1 (ru) | Соединения пиридина | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 |